Pfizer’s shares have been declining for three years, and the company’s forecast for 2026 appears bleak due to significant patent cliffs, particularly for the anticoagulant Eliquis. Additionally, Pfizer has not yet yielded results from clinical trials for potential replacements for Eliquis or its diminishing COVID-19 products. Although a rebound is anticipated in the future, it is unlikely to occur by 2026. Meanwhile, other healthcare companies like Vertex Pharmaceuticals and Medtronic may outperform Pfizer this year.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
